David B. Fischer
Known title: DirectorCIK: 0001305182
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Balchem (BCPC) Seen Trading Below Fair Value. A recent Yahoo analysis notes that BCPC is priced below its estimated fair value. The comment highlights a possible valuation gap while the stock sits near a long‑standing support level. This context may be useful for investors reviewing the company's current price relative to its fundamentals.
Transaction History
| INGR | ▼ Sell | Open Market | 1,662 | $170K | 8/5/2026 | View on chart |
| INGR | ▲ Buy | Grant | 1,797 | $193K | 5/20/2026 | View on chart |
| INGR | ▲ Buy | Grant | 380 | $43K | 3/31/2026 | View on chart |
| BCPC | ▲ Buy | Grant | 870 | $0 | 2/11/2026 | View on chart |
| INGR | ▲ Buy | Grant | 371 | $40K | 12/5/2025 | View on chart |
| BCPC | ▲ Buy | Option Exercise | 3,383 | $252K | 12/3/2025 | View on chart |
| BCPC | ▼ Sell | Open Market | 2,000 | $308K | 12/3/2025 | View on chart |
| BCPC | ▲ Buy | Option Exercise | 2,617 | $220K | 12/3/2025 | View on chart |
| BCPC | ▼ Sell | Open Market | 6,000 | $923K | 12/3/2025 | View on chart |
| INGR | ▲ Buy | Grant | 321 | $40K | 9/30/2025 | View on chart |
| INGR | ▲ Buy | Grant | 291 | $40K | 6/30/2025 | View on chart |
| INGR | ▲ Buy | Grant | 302 | $40K | 3/31/2025 | View on chart |
| BCPC | ▲ Buy | Grant | 980 | $0 | 2/12/2025 | View on chart |
| INGR | ▲ Buy | Grant | 275 | $40K | 12/12/2024 | View on chart |
| INGR | ▲ Buy | Grant | 295 | $40K | 9/30/2024 | View on chart |
| INGR | ▲ Buy | Grant | 347 | $40K | 6/28/2024 | View on chart |
| BCPC | ▼ Sell | Open Market | 637 | $98K | 5/8/2024 | View on chart |
| BCPC | ▼ Sell | Open Market | 4,363 | $667K | 5/8/2024 | View on chart |
| INGR | ▲ Buy | Grant | 342 | $40K | 3/29/2024 | View on chart |
| BCPC | ▲ Buy | Grant | 540 | $0 | 2/8/2024 | View on chart |
| INGR | ▲ Buy | Grant | 361 | $38K | 12/11/2023 | View on chart |
| INGR | ▲ Buy | Grant | 377 | $37K | 9/29/2023 | View on chart |
| BCPC | ▼ Sell | Open Market | 3,800 | $500K | 9/11/2023 | View on chart |
| INGR | ▲ Buy | Grant | 354 | $38K | 6/30/2023 | View on chart |
| INGR | ▲ Buy | Grant | 381 | $37K | 3/31/2023 | View on chart |
| BCPC | ▼ Sell | Open Market | 3,000 | $381K | 3/20/2023 | View on chart |
| BCPC | ▲ Buy | Grant | 530 | $0 | 2/8/2023 | View on chart |
| INGR | ▲ Buy | Grant | 450 | $37K | 10/3/2022 | View on chart |
| INGR | ▲ Buy | Grant | 422 | $37K | 7/1/2022 | View on chart |
| INGR | ▲ Buy | Grant | 438 | $37K | 4/1/2022 | View on chart |
| BCPC | ▲ Buy | Grant | 509 | $0 | 2/10/2022 | View on chart |
| INGR | ▲ Buy | Grant | 391 | $38K | 1/3/2022 | View on chart |
| INGR | ▲ Buy | Grant | 359 | $32K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target
Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.
Ingredion Sees Rising Clean-Label Demand, UBS Lowers Target. Demand for clean‑label ingredients is growing, which has helped lift Ingredion’s share price. UBS kept a neutral stance but cut its price target to $104, citing uncertainty about future momentum. The company’s T&HS solutions are being examined for their ability to sustain growth into 2026.